In another Phase 2 study (NCT03032484), denifanstat was administered with bevacizumab targeting vascular endothelial growth factor A (VEGF-A) in patients with recurrent high-grade astrocytomas, including glioblastoma, targeting both metabolic and angiogenic pathways, and the results showed that the combination was safe and promising signals were detected in treated patients, warranting further study (Kelly et al., 2023). Here, VEGFA is linked to astrocytoma (excluding glioblastoma).